Betamethasone Sodium Phosphate — Drug Intelligence | 45 EU Trials

Filter these 45 trials by condition, phase, country and more.

Open in Search →

45 Registered trials

16 Recruiting

23 Completed trials

30 Sponsors

23 Countries

Phase III

Phase II

Phase III: 20 Phase II/III: 3 Phase II: 13 Phase I/II: 4 Phase IV: 4 Phase I (FiH): 1

Oversight events:

1 serious breach 1 temporary halt 2 urgent safety measures 2 unexpected events across 4 trials

View oversight register →

Indications tested

Diffuse large B-cell lymphoma 4 Small cell lung cancer extensive stage 2 Follicular lymphoma stage III 1 Non-small cell lung cancer metastatic 1 Rheumatoid arthritis 1 Adenovirus infection 1 Follicular lymphoma stage II 1 Mantle cell lymphoma 1 Retinitis pigmentosa 1 Crigler-Najjar syndrome 1 H1N1 influenza 1 Primary myelofibrosis 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 5 Assistance Publique Hopitaux De Paris 4 Genmab A/S 4 Celgene Corp. 3 Amgen Inc. 2 AstraZeneca AB 2 Kite Pharma Inc. 2 Universitaetsklinikum Heidelberg AöR 2 Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino 1 Azienda Provinciale Per I Servizi Sanitari 1 Eli Lilly & Co. 1 Fakultni Nemocnice Plzen 1

All trials — page 2

45 total

A Phase 2 Study of Obexelimab in Patients with Systemic Lupus Erythematosus Ended

2024-510584-37-00 Phase II 10 countries Zenas Biopharma (USA) LLC
A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended

2024-511304-16-00 Phase II 5 countries Celgene Corp.
A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended

2023-510178-15-00 Phase III 17 countries Celgene Corp.
Long Term Follow-Up study of Gene Therapy Trial for Patients with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defec… Ended

2024-511411-25-00 Phase III 6 countries Janssen Cilag International
A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom… Ended

2022-501380-40-00 Phase II 3 countries Merck Sharp & Dohme LLC
PCL-2 - PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION (… Ended

2024-515037-15-00 Phase II 1 country Assistance Publique Hopitaux De Paris
A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
The REST (Replacing Steroids in the transplant ineligible) study. Ended

2023-510194-34-00 Phase II 2 countries Oslo University Hospital HF
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Phase III 11 countries Incyte Corp.
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Phase I/II 9 countries Genmab A/S
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries Genmab A/S
Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients Ended

2024-516102-36-00 Phase II 1 country Assistance Publique Hopitaux De Paris
PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended

2024-515953-52-00 Phase III 8 countries Sobi Inc.
Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer Ended

2024-511144-86-00 Phase III 6 countries AstraZeneca AB
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Ended

2023-506777-36-00 Phase II/III 6 countries Eli Lilly & Co.
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
Transfer of prednisolone into human breast milk and plasma of breastfeeding children Ended

2023-508913-18-00 Phase IV 1 country Uppsala Universitet
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended

2024-510745-34-00 Phase II/III 4 countries Regeneron Pharmaceuticals Inc.

Showing 25–45 of 45 trials

← All drugs A–Z